GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026

29 Jan 2026 00:21 CET

Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its Extraordinary General Meeting held today at 3:00 p.m. approved all resolutions submitted to shareholders, with the exception of the 8th resolution relating to a reserved capital increase, which was rejected.

Shareholders notably approved the renewal of all financial authorizations, replacing those previously used, thereby providing the Company with the financial flexibility required to pursue its strategy.

The meeting was chaired by Jan Eryk Umiastowski, Deputy Chief Executive Officer and Chief Financial Officer, who answered one written question. The question and the response are available on the Company’s website. He also provided clarifications in response to questions raised by shareholders during the meeting.

The rejection of the 8th resolution, which has no impact on financial authorizations, does not affect the Company’s ability to carry out capital transactions.

The results of the vote by resolution and the replay of the Annual General Meeting are available on the Company's website in the Investors section (www.gensight-biologics.com/investors-media).

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. GS010 is currently in clinical development, has not to date been granted marketing authorization in France or any other jurisdiction, and is therefore not available commercially. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260128489702/en/

GenSight Biologics
Chief Financial Officer
Jan Eryk Umiastowski
jeumiastowski@gensight-biologics.com